eligibility_summary
Eligible: adults (≥18) with relapsed/refractory DLBCL not eligible for transplant, starting commercially available tafasitamab plus lenalidomide after consenting, tafasitamab prescribed independent of study, able to give informed consent. Exclude: participation in an interventional trial, unreliable data per physician, or tafasitamab started before consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Italian multicenter prospective observational cohort evaluating real‑world effectiveness/safety of tafasitamab + lenalidomide induction followed by tafasitamab monotherapy in non‑transplant‑eligible relapsed/refractory DLBCL. Drugs/interventions and mechanisms: • Tafasitamab (MOR208): Fc‑engineered humanized anti‑CD19 monoclonal antibody, targets CD19 on B cells, blocking BCR‑related signaling and inducing tumor cell death via antibody‑dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), with direct pro‑apoptotic effects. • Lenalidomide: oral immunomodulatory drug (IMiD), binds cereblon (CRBN) E3 ligase, leading to IKZF1/3 degradation, enhancing T‑ and NK‑cell activation and augmenting antibody‑mediated cytotoxicity, also antiproliferative/anti‑angiogenic. Cells/pathways targeted: CD19+ malignant B cells, B‑cell receptor/CD19 axis, innate immunity (NK cell ADCC, macrophage ADCP) and adaptive immunity (T‑cell activation via CRBN‑IKZF).